[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616693":3},{"organization":4,"outcomesModule":7,"designInfo":33,"detailedDescription":40,"studyPopulation":32,"armGroups":41,"interventions":52,"overallOfficials":58,"centralContacts":62,"locations":72,"responsibleParty":90,"collaborators":92,"id":95,"slug":32,"hasResults":96,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":32,"eligibilityCriteria":100,"healthyVolunteers":96,"sex":101,"minAge":102,"maxAge":32,"enrollmentInfo":103,"targetDuration":32,"studyType":106,"phases":107,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":114,"whyStopped":32,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"Hospital Universitario San Ignacio","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":32},[9],{"measure":10,"description":11,"timeFrame":12},"Time in Range","To compare the efficacy defined as time in range between 70 - 180 mg\u002Fdl of the TR-CGM compared to isCGM in patients diagnosed with T2DM treated with insulin who use CGM as part of usual clinical practice in follow-up at the endocrinology unit of the San Ignacio University Hospital.","12 weeks",[14,17,20,23,26,29],{"measure":15,"description":16,"timeFrame":12},"Proportion of patients with a ≥5% increase in TIR","Compare the proportion of patients with a ≥5% increase in TIR 70-180 mg\u002Fdl compared to the initial value.",{"measure":18,"description":19,"timeFrame":12},"TAR","To compare percentage of time in hyperglycemia range \\>180 and \\>250 mg\u002Fdl",{"measure":21,"description":22,"timeFrame":12},"TBR \u003C70 mg\u002Fdl","To compare the proportion of patients with a %TBR \\\u003C70 mg\u002FdL to less than 4%",{"measure":24,"description":25,"timeFrame":12},"TBR \u003C54 mg\u002Fdl","To compare the proportion of patients with a %TBR \\\u003C54 mg\u002FdL to less than 1%",{"measure":27,"description":28,"timeFrame":12},"Severe hypoglycemia","To compare the incidence of severe hypoglycemia, hospitalizations, and emergency department visits.",{"measure":30,"description":31,"timeFrame":12},"Satisfaction with the device","To compare satisfaction with the device using the \"Questionnaire on experience with glucose monitoring (C-EMC)\" at the end of the follow-up.",null,{"allocation":34,"interventionModel":35,"interventionModelDescription":36,"primaryPurpose":37,"observationalModel":32,"timePerspective":32,"maskingInfo":38},"RANDOMIZED","PARALLEL","open-label randomized clinical trial","TREATMENT",{"masking":39,"maskingDescription":32,"whoMasked":32},"NONE","All patients diagnosed with type 2 diabetes (T2D) who meet the inclusion criteria will be identified (see inclusion and exclusion criteria). They will then be invited to participate in the study and asked to sign an informed consent form. Demographic data, baseline clinical characteristics, and clinical tests related to metabolic control will be collected.\n\nVisit 0 (V0): Informed consent signature and basal CGM system installation will be verified.\n\nVisit 1 (V1): CGM data will be downloaded. All enrolled patients will receive the same instructions for device use and management of high and low glucose levels, according to standard clinical procedures. Then, randomization will be performed by someone who is blinded to the clinical characteristics of each patient and is not part of the research group. The allocation given by this mechanism cannot be changed by the treating physicians.\n\n* Usual care + TR-CGM group: Patients in this group will receive a continuous interstitial glucose monitoring (CIGM) sensor via the FreeStyle Libre 2 Plus device and LibreLink app® (Abbott Diabetes Care, Inc., Alameda, CA). High alarms greater than 250 mg\u002FdL and low glucose alerts less than 70 mg\u002FdL will be programmed. All participants will be instructed to change their sensor according to the manufacturer's recommendations: every 15 days for the TR-CGM group.\n* Usual care + CIGM group: Patients in this group will receive a CIGM sensor using the FreeStyle Libre 2 device (Abbott Diabetes Care Inc., Alameda, CA, USA). High alarms \\>250 mg\u002FdL and low glucose alerts \\\u003C70 mg\u002FdL will be programmed. Additionally, they will be instructed to perform at least eight scans daily to avoid data loss. All participants were instructed to change their sensors according to the manufacturer's recommendations: every 15 days for isCGM.\n\nStandard Care (Applies to Both Groups):\n\nAll patients should be assessed by the diabetes clinic's nutrition service, which will provide basic dietary and physical activity recommendations.\n\nAll patients will be instructed in basal and\u002For prandial insulin titration, as appropriate.",[42,46],{"label":43,"type":44,"description":45,"interventionNames":32},"isCGM","NO_INTERVENTION","Usual Care + isCGM Group: Patients in this group will have the FreeStyle Libre 2 continuous interstitial glucose monitoring sensor (Abbott Diabetes Care Inc., Alameda, CA, USA) inserted. High glucose alarms (\\>250 mg\u002FdL) and low glucose alerts (\\\u003C70 mg\u002FdL) will be programmed. They will also be instructed to perform at least eight scans daily to avoid data loss. All participants were instructed to replace their sensors according to the manufacturer's recommendations: every 15 days for isCGM.",{"label":47,"type":48,"description":49,"interventionNames":50},"RT-CGM","EXPERIMENTAL","• Usual care + TR-CGM group: Patients in this group will undergo insertion of a continuous interstitial glucose monitoring (CGM) sensor using the FreeStyle Libre 2 Plus device and LibreLink app® (Abbott Diabetes Care, Inc., Alameda, CA, USA). The sensor will be programmed with high glucose alarms (\\>250 mg\u002FdL) and low glucose alerts (\\\u003C70 mg\u002FdL). All participants will be instructed to replace their sensor according to the manufacturer's recommendations: every 15 days for TR-CGM.",[51],"Device: real time Continuous Glucose Monitoring",[53],{"type":54,"name":55,"description":49,"armGroupLabels":56,"otherNames":57},"DEVICE","real time Continuous Glucose Monitoring",[47],[47],[59],{"name":60,"affiliation":5,"role":61},"Diana C Henao-Carrillo, Endocrinologyst","PRINCIPAL_INVESTIGATOR",[63,69],{"name":64,"role":65,"phone":66,"phoneExt":67,"email":68},"Diana C Henao, Endocrinologyst","CONTACT","+57 601 5946161","2817","dchenao@husi.org.cp",{"name":70,"role":65,"phone":66,"phoneExt":67,"email":71},"Adriana L Gonzáles, Nutricionist","algomez@husi.org.co",[73],{"facility":5,"status":32,"city":74,"state":32,"zip":75,"country":76,"countryCode":77,"cosmosGeoPoint":78,"geoPoint":83,"contacts":84},"Bogotá","111121","Colombia","CO",{"type":79,"coordinates":80},"Point",[81,82],-74.08175,4.60971,{"lat":82,"lon":81},[85,87,89],{"name":60,"role":65,"phone":66,"phoneExt":67,"email":86},"dchenao@husi.org.co",{"name":88,"role":65,"phone":66,"phoneExt":67,"email":71},"Adriana G Gómez-Velasquez, Nutricionist",{"name":60,"role":61,"phone":32,"phoneExt":32,"email":32},{"type":91,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR",[93],{"name":94,"class":6},"Pontificia Universidad Javeriana","100616693",false,"NCT07308925","Real-time Continuous Glucose Monitoring Compared With Intermittent Continuous Glucose Monitoring in People With Type 2 Diabetes Treated With Insulin.","Effectiveness of Using Real-time Continuous Glucose Monitoring Compared With Intermittent Continuous Glucose Monitoring in People With Type 2 Diabetes Treated With Insulin.","Inclusion Criteria:\n\n* Minimum age of 35 years.\n* HbA1c \\>7.0%\n* Treatment with one or more insulin injections.\n* Stable medication regimen for the 3 months prior to study entry.\n* Insulin treatment for ≥3 months with a stable dose prior to entry, with fasting blood glucose between 70 and 130 mg\u002FdL.\n* Availability of an NFC-enabled smartphone.\n\nExclusion Criteria:\n\n* Pregnancy or planning to become pregnant during the study period.\n* History of bariatric surgery within the year prior to study entry or plans to undergo bariatric surgery during the study.\n* Having a condition that would likely require an MRI during the study period.\n* Use of medications containing high doses of ascorbic acid (\\>2000 mg\u002Fday), as it may falsely increase sensor readings.\n* Concomitant illness or condition that may compromise patient safety, including, but not limited to, serious mental illness, a diagnosed or suspected eating disorder, or any long-term medical\u002Funmanageable disorder.\n* GFR less than 30 ml\u002Fmin.\n* Psychiatric condition that interferes with study-related tasks.\n* Known (or suspected) significant allergy to medical-grade adhesives.","ALL","35 Years",{"count":104,"type":105},108,"ESTIMATED","INTERVENTIONAL",[108],"NA","The objective is to compare the efficacy of TR-CGM versus isCGM in patients diagnosed with T2D who are treated with insulin and use CGM, as defined by time in range between 70 and 180 mg\u002FdL.\n\nAn open-label clinical trial will be conducted. Patients with T2D who use intermittent glucose monitoring and insulin with poor metabolic control will be included. They will be randomized to continue with isCGM or RT-CGM.\n\nThe primary outcome: %TIR 70-180 mg\u002FdL.",[111],"Type 2 Diabetes",[111,113,10],"Continuous Glucose Monitoring","NOT_YET_RECRUITING","2025-12-27",{"date":117,"type":118},"2025-12-30","ACTUAL",{"date":120,"type":105},"2026-01-31",{"date":122,"type":105},"2028-12-30",{"name":5,"class":6},1]